Navigation Links
ASPS Studies Re-Evaluate Psychological Benefits and Health Concerns of Silicone Breast Implants
Date:1/3/2008

Effect on Body Image, Cancer, and Breast-feeding Examined

ARLINGTON HEIGHTS, Ill., Jan. 3 /PRNewswire-USNewswire/ -- Plastic surgeons are re-evaluating past scientific findings and developing new knowledge about the effects of silicone breast implants. A recent supplement to Plastic and Reconstructive Surgery(R) (PRS), the official medical journal of the American Society of Plastic Surgeons (ASPS), sheds new light on the psychological impact and health concerns of silicone breast implants.

Body Image

One review of important recent studies refuted a common perception - women who want breast augmentation do not suffer from lower overall body image than other women.

"Breast augmentation patients do not have a poorer overall self-image, nor are they more self-critical and preoccupied with their appearance than other women," said Mary McGrath, MD, ASPS Member Surgeon and study author. "It appears it is their significant dissatisfaction with their breasts that serves as the motivation for surgery, not a poor overall body image."

The positive effect of breast augmentation on women's thoughts and feelings is also limited to their breasts. After surgery, they report being less embarrassed about their breasts and spending less time feeling upset about and camouflaging their breasts.

Cancer Risk

While some studies have raised concerns about the potential link between silicone breast implants and breast cancer, others have suggested the implants could cause other types of cancer (cervical, vulvar, lung, etc). A National Cancer Institute (NCI) review of past epidemiologic studies showed little support for an increased risk of cancer among breast implant patients.

"At present, there is no convincing evidence that breast implants alter the risk of cancer," said Louise Brinton, Ph.D., NCI, and study author. "The few increases in risk that have been noted in studies appear to be largely attributable to lifest
'/>"/>

SOURCE American Society of Plastic Surgeons
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Winemaking waste proves effective against disease-causing bacteria in early studies
2. Brain imaging and genetic studies link thinking patterns to addiction
3. Top10 research advances include studies on genetics and stem cell research, stents
4. Recent studies confirm significant underuse of colorectal cancer screening
5. New studies on cancer and schizophrenia, depression and heart disease, trauma and autism
6. Pharmion and Methylgene Report Favorable Results for Phase 2 MGCD0103 Single- Agent Studies in Relapsed or Refractory Lymphomas at the 49th American Society of Hematology (ASH) Meeting
7. Studies elucidate genetic links between cancer and schizophrenia
8. Studies find stable sleep patterns and regular routines may improve outcomes in bipolar disorder
9. Observational Studies Often Overshadow Clinical Research
10. Studies review smoking among college freshmen and tobacco use by adolescents with ADHD
11. Breaking Studies at AARC Congress Show Masimo SET and Masimo Rainbow SET to be Accurate, Effective and Uniquely Beneficial in Detecting and Tracking Disease States
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Within3 Expands into Mobile Applications 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program 2American Chemical Societys Weekly PressPac June 3 2009 8740 1American Chemical Societys Weekly PressPac June 3 2009 8740 2American Chemical Societys Weekly PressPac June 3 2009 8740 3American Chemical Societys Weekly PressPac June 3 2009 8740 4American Chemical Societys Weekly PressPac June 3 2009 8740 5American Chemical Societys Weekly PressPac June 3 2009 8740 6American Chemical Societys Weekly PressPac June 3 2009 8740 7American Chemical Societys Weekly PressPac June 3 2009 8740 8American Chemical Societys Weekly PressPac June 3 2009 8740 9American Chemical Societys Weekly PressPac June 3 2009 8740 10Warner Chilcott to Present at the Goldman Sachs 30th Annual Healthcare Conference 48171 1Video 3A CVS pharmacy Kicks Off 8th Annual ALS Fundraising Campaign in Stores Nationwide 48169 1Video 3A CVS pharmacy Kicks Off 8th Annual ALS Fundraising Campaign in Stores Nationwide 48169 2Video 3A CVS pharmacy Kicks Off 8th Annual ALS Fundraising Campaign in Stores Nationwide 48169 3